FATE Q1 2017 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FATEFate Therapeutics, Inc.

$142M

Q1 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M-22.3% YoY

Gross Profit

-$7M-675.7% margin

Operating Income

-$10M-970.9% margin

Net Income

-$10M-986.0% margin

EPS (Diluted)

$-0.24

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$8M

Stock-Based Comp.

$867,000

Balance Sheet

Total Assets

$85M

Total Liabilities

$21M

Stockholders' Equity

$64M

Cash & Equivalents

$41M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$1M	-22.3%
Gross Profit	-$7M	-$5M	-30.6%
Operating Income	-$10M	-$8M	-26.0%
Net Income	-$10M	-$8M	-20.9%